Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and Aims</h3><p>Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease worldwide, but no effective pharmacological therapeutics are available for clinical use. Nonalcoholic steatohepatitis (NASH) is the more severe stage of NAFLD. During this progress, dysregulation of endoplasmic reticulum (ER) related pathways and proteins is one of the predominant hallmarks. Here, we aimed to reveal the role of RNF5, an ER-localized E3 ubiquitin-protein ligase, in NASH and to explore its underlying mechanism.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Approach and Results</h3><p>We firstly inspected the expression level of RNF5 and found that RNF5 was markedly decreased in livers with NASH in multispecies including human. We then introduced adenoviruses for Rnf5 overexpression or knockdown into primary mouse hepatocytes, and found that palmitic acid/oleic acid (PAOA)-induced lipid accumulation and inflammation in hepatocytes were markedly attenuated by Rnf5 overexpression but exacerbated by <i>Rnf5</i> gene silencing. Hepatocyte-specific <i>Rnf5</i> knockout significantly exacerbated hepatic steatosis, inflammatory response and fibrosis in mice challenged with diet-induced NASH. Mechanistically, we identified HRD1 as a novel binding partner of RNF5 by systematic interactomics analysis. RNF5 directly bound to HRD1 and promoted its lysine 48 (K48)- and K33-linked ubiquitination and subsequent proteasomal degradation. Furthermore, Hrd1 overexpression significantly exacerbated PAOA-induced lipid accumulation and inflammation, and shRNA-mediated <i>Hrd1</i> knockdown exerted the opposite effects. Notably, <i>Hrd1</i> knockdown significantly disminished PAOA-induced lipid deposition and upregulation of related genes resulted from Rnf5 ablation in hepatocytes. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>These data indicate that RNF5 inhibits NASH progression by targeted degradation HRD1 for ubiquitin- mediated proteasomal pathway. Targeting the RNF5-HRD1 axis may provide new insights in the pathogenesis of NASH, and pave the way for developing novel strategies for NASH prevention and treatment.</p></section>

The deubiquitinating enzyme 13 retards non-alcoholic steatohepatitis via blocking inactive rhomboid protein 2-dependent pathway

Terf2ip Deficiency Accelerates Non-Alcoholic Steatohepatitis Through Regulating Lipophagy and Fatty Acid Oxidation Via Sirt1/AMPK Pathway

USP14 Governs CYP2E1 to Promote Nonalcoholic Fatty Liver Disease Through Deubiquitination and Stabilization of HSP90AA1

Ubiquitin-specific Peptidase 10 Ameliorates Hepatic Steatosis in Nonalcoholic Steatohepatitis Model by Restoring Autophagic Activity.

USP13 ameliorates nonalcoholic fatty liver disease through inhibiting the activation of TAK1

USP18 protects against hepatic steatosis and insulin resistance via its DUB activity.

Deubiquitinase USP18 inhibits hepatic stellate cells activation and alleviates liver fibrosis via regulation of TAK1 activity

USP13 ameliorates metabolic dysfunction-associated steatohepatitis through targeting PTEN

Peroxisome Proliferator-Activated Receptor Γ Coactivator 1α Maintains NAD+ Bioavailability Protecting Against Steatohepatitis

USP9X-mediated NRP1 deubiquitination promotes liver fibrosis by activating hepatic stellate cells

Ubiquitin-specific peptidase 25 ameliorates hepatic steatosis by stabilizing peroxisome proliferator-activated receptor alpha

The E3 ubiquitin-protein ligase Trim31 alleviates non-alcoholic fatty liver disease by targeting Rhbdf2 in mouse hepatocytes

Ubiquitin-Specific Peptidase 10 (USP10) Inhibits Hepatic Steatosis, Insulin Resistance, and Inflammation Through Sirt6

The E3 Ubiquitin Ligase Ring Finger Protein 5 Ameliorates NASH Through Ubiquitin‐Mediated Degradation of 3‐Hydroxy‐3‐Methylglutaryl CoA Reductase Degradation Protein 1

Tripartite motif containing 26 prevents steatohepatitis progression by suppressing C/EBPδ signalling activation

Activation of the Aryl Hydrocarbon Receptor Sensitizes Mice to Nonalcoholic Steatohepatitis by Deactivating Mitochondrial Sirtuin Deacetylase Sirt3.

Inhibition of HSP20 Ameliorates Steatotic Liver Disease by Stimulating ERK2-dependent Autophagy

KIRA8 attenuates non-alcoholic steatohepatitis through inhibition of the IRE1α/XBP1 signalling pathway

Ubiquitin-specific protease 4 is an endogenous negative regulator of metabolic dysfunctions in nonalcoholic fatty liver disease.

Hepatocyte phosphatase DUSP22 mitigates NASH-HCC progression by targeting FAK

Proteome-wide analysis of USP14 substrates revealed its role in hepatosteatosis via stabilization of FASN